Open AccessImmune checkpoint inhibitor-induced pneumonitis: Incidence, clinical characteristics, and outcomes
Author(s) -
Harsha Banavasi,
Seongho Kim,
Samer Alkassis,
Asil Daoud,
Amir Laktineh,
Misako Nagasaka,
Ammar Sukari,
Ayman O. Soubani
Publication year - 2021
Publication title -
hematology/oncology and stem cell therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.666
H-Index - 22
eISSN - 1658-3876
pISSN - 2589-0646
DOI - 10.1016/j.hemonc.2021.09.005
Subject(s) - pneumonitis , medicine , incidence (geometry) , immune system , immunology , lung , physics , optics
Immune checkpoint inhibitors (ICIs) are the newest class of anticancer drugs. Pneumonitis is increasingly being recognized as a potential complication of these agents.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom